Advertisement

Tumor Biology

, Volume 36, Issue 7, pp 4979–4986 | Cite as

Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer

  • Fabien Gueugnon
  • Aurélia Barascu
  • Konstantinos Mavridis
  • Agnès Petit-Courty
  • Sylvain Marchand-Adam
  • Valérie Gissot
  • Andreas Scorilas
  • Serge Guyetant
  • Yves Courty
Research Article

Abstract

The KLK13 gene is dysregulated in several carcinomas, and its expression levels seem to be associated with disease prognosis. The aim of our study was to investigate the prognostic potential of KLK13 mRNA expression for patients with nonsmall cell lung cancer (NSCLC). Total RNA was isolated from cancerous and normal tissues from a cohort of 128 NSCLC patients. The KLK13 mRNA transcription levels were measured using a sensitive quantitative RT-PCR method. The results were normalized by dividing the KLK13 mRNA values with the geometric mean of mRNA expression from four reference genes: beta-actin, TATA-binding protein, hypoxanthine phosphoribosyltransferase 1, and acidic ribosomal phosphoprotein P0. The malignant tissues from the majority of patients (59.3 %) contained significantly more KLK13 mRNA transcripts than did the paired nonmalignant tissues (median difference 11.1-fold, P = 0.008). KLK13 was expressed at higher levels in females than that in males (P = 0.021). No other statistically significant association with clinicopathological data was observed. Kaplan-Meier survival analyses demonstrated that patients with KLK13-positive tumors survived significantly longer than those with KLK13-negative ones (P = 0.009). KLK13 expression was also shown to be able to stratify high-risk individuals among patients with early disease stages (P = 0.030). Multivariate Cox regression analysis showed that KLK13 expression is a favorable, independent prognostic indicator of overall survival (OS) (P = 0.024). Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in NSCLC and that its quantitative assessment in tumor tissues can aid in treatment decision making.

Keywords

Lung cancer Tissue kallikrein Biomarker Prognosis 

Abbreviations

KLK

Kallikrein-related peptidase

NSCLC

Nonsmall cell lung cancer

pTNM

Postsurgical pathologic tumor node metastasis

Cp

Crossing point

HR

Hazard ratio

CI

Confidence interval

ADC

Adenocarcinoma

SCC

Squamous cell carcinoma

OSCC

Oral squamous cell carcinoma

Notes

Acknowledgments

The English text was edited by Dr. Owen Parkes. We thank Prof. Pascal Dumont (Tours Hospital) and Lysiane Brick, Géraldine Meunier, Alexandra Fayault, and Aliette Decock-Giraudaud (CIC INSERM 202) for their help in collecting tissues and clinical data. This work was supported by funds from the Ligue Contre le Cancer (Comités d’Indre et Loire, du Morbihan et de la Sarthe).

Conflicts of interest

None.

Supplementary material

13277_2015_3148_MOESM1_ESM.docx (15 kb)
ESM 1 (DOCX 14 kb)
13277_2015_3148_MOESM2_ESM.rtf (150 kb)
ESM 2 (RTF 150 kb)

References

  1. 1.
    Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73–7.PubMedGoogle Scholar
  2. 2.
    Eissa A, Diamandis EP. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol Chem. 2008;389(6):669–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Chao J, Shen B, Gao L, Xia CF, Bledsoe G, Chao L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010;391(4):345–55.CrossRefPubMedGoogle Scholar
  4. 4.
    Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med. 2011;50(2):211–33.PubMedGoogle Scholar
  5. 5.
    Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost. 2009;101(2):222–4.PubMedGoogle Scholar
  8. 8.
    Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, et al. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol. 2013;47(4):319–29.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer. 2002;86(11):1790–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mavridis K, Talieri M, Scorilas A. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem. 2010;391(4):467–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Florou D, Mavridis K, Scorilas A. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol. 2012;33(6):2069–78.CrossRefPubMedGoogle Scholar
  12. 12.
    Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Planque C, Blechet C, Ayadi-Kaddour A, Heuze-Vourc'h N, Dumont P, Guyetant S, et al. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. Biol Chem. 2008;389(6):781–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Yousef GM, Chang A, Diamandis EP. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 2000;275(16):11891–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP. Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers. 2006;21(2):106–10.CrossRefGoogle Scholar
  17. 17.
    Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43(15):1205–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Ishige S, Kasamatsu A, Ogoshi K, Saito Y, Usukura K, Yokoe H, et al. Decreased expression of kallikrein-related peptidase 13: Possible contribution to metastasis of human oral cancer. Mol Carcinog. 2013. doi: 10.1002/mc.22007.PubMedGoogle Scholar
  19. 19.
    Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer. 2002;86(9):1457–64.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009;101(7):1107–13.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034Google Scholar
  22. 22.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Altman DG. Suboptimal analysis using ‘optimal’ cutpoints. Br J Cancer. 1998;78(4):556–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. 2006;66(24):11763–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001;7(4):806–11.PubMedGoogle Scholar
  26. 26.
    Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 2001;61(21):7811–8.PubMedGoogle Scholar
  27. 27.
    Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat. 2003;78(2):149–58.CrossRefPubMedGoogle Scholar
  28. 28.
    Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, et al. Decreased kallikrein 11 messenger RNA expression in lung cancer. Clin Lung Cancer. 2006;8(1):45–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Shigemasa K, Gu L, Tanimoto H, O'Brien TJ, Ohama K. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res. 2004;10(8):2766–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Patsis C, Yiotakis I, Scorilas A. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem. 2012;45(9):623–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2009;101(4):934–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Chou RH, Lin SC, Wen HC, Wu CW, Chang WS. Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun. 2011;409:442–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47(2):173–81.CrossRefPubMedGoogle Scholar
  34. 34.
    Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol. 2007;33(6):763–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Pitz MW, Musto G, Navaratnam S. Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. Can Respir J. 2013;20(1):30–4.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, et al. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol. 2008;15(11):3272–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Lai JC, Wu JY, Cheng YW, Yeh KT, Wu TC, Chen CY, et al. O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells. Anticancer Res. 2009;29(7):2535–40.PubMedGoogle Scholar
  38. 38.
    Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008;14(5):1355–62.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Fabien Gueugnon
    • 1
    • 3
  • Aurélia Barascu
    • 2
    • 3
  • Konstantinos Mavridis
    • 4
  • Agnès Petit-Courty
    • 1
    • 3
  • Sylvain Marchand-Adam
    • 1
    • 3
  • Valérie Gissot
    • 5
  • Andreas Scorilas
    • 4
  • Serge Guyetant
    • 1
    • 3
  • Yves Courty
    • 1
    • 3
  1. 1.INSERM, UMR 1100ToursFrance
  2. 2.Université François RabelaisToursFrance
  3. 3.Centre d’Etude des Pathologies RespiratoiresToursFrance
  4. 4.Department of Biochemistry and Molecular BiologyUniversity of AthensAthensGreece
  5. 5.CIC INSERM 1415, Faculté de MédecineToursFrance

Personalised recommendations